Left Ventricular T-Cell Recruitment Contributes to the Pathogenesis of Heart Failure

  • Tania Nevers
    From the Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (T.N., A.M.S., A.G.-P., A.K., F.V., M.A., N.K.K., R.H.K., R.M.B., P.A.); and the Program in Immunology, Sackler School for Graduate Studies, Department of Medicine, Tufts University School of Medicine, Boston, MA (F.V., R.H.K., P.A.).
  • Ane M. Salvador
    From the Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (T.N., A.M.S., A.G.-P., A.K., F.V., M.A., N.K.K., R.H.K., R.M.B., P.A.); and the Program in Immunology, Sackler School for Graduate Studies, Department of Medicine, Tufts University School of Medicine, Boston, MA (F.V., R.H.K., P.A.).
  • Anna Grodecki-Pena
    From the Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (T.N., A.M.S., A.G.-P., A.K., F.V., M.A., N.K.K., R.H.K., R.M.B., P.A.); and the Program in Immunology, Sackler School for Graduate Studies, Department of Medicine, Tufts University School of Medicine, Boston, MA (F.V., R.H.K., P.A.).
  • Andrew Knapp
    From the Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (T.N., A.M.S., A.G.-P., A.K., F.V., M.A., N.K.K., R.H.K., R.M.B., P.A.); and the Program in Immunology, Sackler School for Graduate Studies, Department of Medicine, Tufts University School of Medicine, Boston, MA (F.V., R.H.K., P.A.).
  • Francisco Velázquez
    From the Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (T.N., A.M.S., A.G.-P., A.K., F.V., M.A., N.K.K., R.H.K., R.M.B., P.A.); and the Program in Immunology, Sackler School for Graduate Studies, Department of Medicine, Tufts University School of Medicine, Boston, MA (F.V., R.H.K., P.A.).
  • Mark Aronovitz
    From the Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (T.N., A.M.S., A.G.-P., A.K., F.V., M.A., N.K.K., R.H.K., R.M.B., P.A.); and the Program in Immunology, Sackler School for Graduate Studies, Department of Medicine, Tufts University School of Medicine, Boston, MA (F.V., R.H.K., P.A.).
  • Navin K. Kapur
    From the Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (T.N., A.M.S., A.G.-P., A.K., F.V., M.A., N.K.K., R.H.K., R.M.B., P.A.); and the Program in Immunology, Sackler School for Graduate Studies, Department of Medicine, Tufts University School of Medicine, Boston, MA (F.V., R.H.K., P.A.).
  • Richard H. Karas
    From the Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (T.N., A.M.S., A.G.-P., A.K., F.V., M.A., N.K.K., R.H.K., R.M.B., P.A.); and the Program in Immunology, Sackler School for Graduate Studies, Department of Medicine, Tufts University School of Medicine, Boston, MA (F.V., R.H.K., P.A.).
  • Robert M. Blanton
    From the Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (T.N., A.M.S., A.G.-P., A.K., F.V., M.A., N.K.K., R.H.K., R.M.B., P.A.); and the Program in Immunology, Sackler School for Graduate Studies, Department of Medicine, Tufts University School of Medicine, Boston, MA (F.V., R.H.K., P.A.).
  • Pilar Alcaide
    From the Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (T.N., A.M.S., A.G.-P., A.K., F.V., M.A., N.K.K., R.H.K., R.M.B., P.A.); and the Program in Immunology, Sackler School for Graduate Studies, Department of Medicine, Tufts University School of Medicine, Boston, MA (F.V., R.H.K., P.A.).

説明

<jats:sec> <jats:title>Background—</jats:title> <jats:p>Despite the emerging association between heart failure (HF) and inflammation, the role of T cells, major players in chronic inflammation, has only recently begun to be explored. Whether T-cell recruitment to the left ventricle (LV) participates in the development of HF requires further investigation to identify novel mechanisms that may serve for the design of alternative therapeutic interventions.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods and Results—</jats:title> <jats:p> Real-time videomicroscopy of T cells from nonischemic HF patients or from mice with HF induced by transverse aortic constriction revealed enhanced adhesion to activated vascular endothelial cells under flow conditions in vitro compared with T cells from healthy subjects or sham mice. T cells in the mediastinal lymph nodes and the intramyocardial endothelium were both activated in response to transverse aortic constriction and the kinetics of LV T-cell infiltration was directly associated with the development of systolic dysfunction. In response to transverse aortic constriction, T cell–deficient mice (T-cell receptor, TCRα <jats:sup>−/−</jats:sup> ) had preserved LV systolic and diastolic function, reduced LV fibrosis, hypertrophy and inflammation, and improved survival compared with wild-type mice. Furthermore, T-cell depletion in wild-type mice after transverse aortic constriction prevented HF. </jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions—</jats:title> <jats:p>T cells are major contributors to nonischemic HF. Their activation combined with the activation of the LV endothelium results in LV T-cell infiltration negatively contributing to HF progression through mechanisms involving cytokine release and induction of cardiac fibrosis and hypertrophy. Reduction of T-cell infiltration is thus identified as a novel translational target in HF.</jats:p> </jats:sec>

収録刊行物

被引用文献 (3)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ